Tranilast restenosis

Tranilast Inhibits SMC migration and proliferation, decreases collagen synthesis TREAT (25) TREAT-2 (26) PRESTO (27) Lower restenosis Lower restenosis No difference... [Pg.187]

Abbreviations CDK, cyclin-dependent kinase CREST, cilostazol for restenosis trial MACE, major adverse cardiac events ORAR, oral rapamycin to prevent restenosis ORBIT, oral rapamune to inhibit restenosis REAR, peroxisome proliferator-activated receptor PRESTO, prevention of restenosis with tranilast and its outcomes SMC. smooth muscle cell ThR, target lesion revascularization tREAT, Tranilast restenosis following angioplasty trials TVR, target vessel failure. ... [Pg.187]

Tamai H, Katoh O, Suzuki S. Impact of tranilast on restenosis after coronary angioplasty Tranilast Restenosis Following Angioplasty Trial (TREAT) Am Heart J 1999 138 968- 975,... [Pg.192]

Holmes DR, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its outcomes (PRESTO) Trial. Circulation 2002 106 1243-1250. [Pg.193]

Kao J, Tobis J, McClelland RL, et al. Investigators in the Prevention of Restenosis with Tranilast and its Outcomes Trial. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004 93 1347-1350, A5. [Pg.481]

Kosuga K, Tamai H, Ueda K, et al. Effectiveness of tranilast on restenosis after directional coronary atherectomy. Am Heart J 1997 134 712-718. [Pg.289]

Holmes D, Fitzgerald P, Goldberg S, et al. The PRESTO (Prevention of Restenosis with Tranilast and Its Outcomes) protocol A double-blind, placebo-controlled trial. Am Heart J 2000 139 23-31. [Pg.289]

It is well known that diabetic patients undergoing coronary interventions have worse chnical and angiographic outcomes in comparison with nondiabetic patients. In the retrospective analysis of the PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) trial the effect of different anti-diabetic treatment was analysed [40] in 1,110 diabetic patients who received non-sensitizer therapy (insulin and/or sulfonylureas) and in 887 patients who were treated with sensitizers (metformin with or without additional therapy). Compared with patients on non-sensitizer therapy, those on sensitizer therapy showed an adjusted OR of 0.72 p = 0.005 for any clinical event. The differences between the non-sensitizer therapy group and the sensitizer group were attributable mainly to decreased rates of death (OR = 0.39 p = 0.007) and myocardial infarction (OR = 0.31 p = 0.002). In this retrospective analysis, use of metformin in diabetics undergoing coronary interventions appeared to decrease adverse clinical events, especially death and myocardial infarction, compared with diabetic patients treated with non-sensitizer therapy. [Pg.82]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...